© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 23, 1918-1925,
December 6, 2000
© 2000 Oxford University Press
REPORT |
Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
Affiliations of authors: S. Signoretti, M. Loda, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; R. Montironi, University of Ancona, Italy; J. Manola (Department of Biostatistics), A. Altimari, C. Tam, L. Hlatky, P. Hahnfeldt, P. Kantoff (Department of Adult Oncology), Dana-Farber Cancer Institute; G. Bubley, S. Balk, I. Kaplan, Departments of Medicine and Radiation Therapy, Beth Israel Deaconess Medical Center, Boston; G. Thomas, Department of Pathology, University of California at Los Angeles.
Correspondence to: Massimo Loda, M.D., Department of Adult Oncology, Dana-Farber Cancer Institute, Dana 740B, 44 Binney St., Boston, MA 02215 (e-mail: massimo_loda{at}dfci.harvard.edu).
Background: Human prostate cancers are initially androgen dependent but ultimately become androgen independent. Overexpression of the Her-2-neu receptor tyrosine kinase has been associated with the progression to androgen independence in prostate cancer cells. We examined the expression of Her-2-neu in normal and cancerous prostate tissues to assess its role in the progression to androgen independence. Methods: Prostate cancer tissue sections were obtained from 67 patients treated by surgery alone (UNT tumors), 34 patients treated with total androgen ablation therapy before surgery (TAA tumors), and 18 patients in whom total androgen ablation therapy failed and who developed bone metastases (androgen-independent [AI] disease). The sections were immunostained for Her-2-neu, androgen receptor (AR), prostate-specific antigen (PSA), and Ki-67 (a marker of cell proliferation) protein expression. Messenger RNA (mRNA) levels and gene amplification of Her-2-neu were examined by RNA in situ hybridization and fluorescent in situ hybridization(FISH), respectively, in a subset of 27 tumors (nine UNT, 11 TAA, and seven AI). All statistical tests were two-sided. Results: Her-2-neu protein expression was statistically significantly higher in TAA tumors than in UNT tumors with the use of two different scoring methods (P = .008 and P = .002). The proportion of Her-2-neu-positive tumors increased from the UNT group (17 of 67) to the TAA group (20 of 34) to the AI group (14 of 18) (P<.001). When compared with UNT tumors, tumor cell proliferation was higher in AI tumors (P = .014) and lower in TAA tumors (P<.001). All tumors expressed AR and PSA proteins. Although Her-2-neu mRNA expression was high in TAA and AI tumors, no Her-2-neu gene amplification was detected by FISH in any of the tumor types. Conclusions: Her-2-neu expression appears to increase with progression to androgen independence. Thus, therapeutic targeting of this tyrosine kinase in prostate cancer may be warranted.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Liu, J. Q. Mo, Q. Hu, G. Boivin, L. Levin, S. Lu, D. Yang, Z. Dong, and S. Lu Targeted Overexpression of Vav3 Oncogene in Prostatic Epithelium Induces Nonbacterial Prostatitis and Prostate Cancer Cancer Res., August 1, 2008; 68(15): 6396 - 6406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Lyons, S. Rao, W. Balkan, J. Faysal, C. A. Maiorino, and K. L. Burnstein Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer Mol. Endocrinol., March 1, 2008; 22(3): 597 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Domingo-Domenech, P. L. Fernandez, X. Filella, A. Martinez-Fernandez, R. Molina, E. Fernandez, A. Alcaraz, J. Codony, P. Gascon, and B. Mellado Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel Ann. Onc., February 1, 2008; 19(2): 269 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Shariat, K. Bensalah, J. A. Karam, C. G. Roehrborn, A. Gallina, Y. Lotan, K. M. Slawin, and P. I. Karakiewicz Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer Clin. Cancer Res., September 15, 2007; 13(18): 5377 - 5384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Qin, D. Iliopoulos, T. Nakamura, S. Costinean, S. Volinia, T. Druck, J. Sun, H. Okumura, and K. Huebner Wwox Suppresses Prostate Cancer Cell Growth through Modulation of ErbB2-Mediated Androgen Receptor Signaling Mol. Cancer Res., September 1, 2007; 5(9): 957 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Casimiro, O. Rodriguez, L. Pootrakul, M. Aventian, N. Lushina, C. Cromelin, G. Ferzli, K. Johnson, S. Fricke, F. Diba, et al. ErbB-2 Induces the Cyclin D1 Gene in Prostate Epithelial Cells In vitro and In vivo Cancer Res., May 1, 2007; 67(9): 4364 - 4372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ganly, S. Talbot, D. Carlson, A. Viale, E. Maghami, I. Osman, E. Sherman, D. Pfister, S. Chuai, A. R. Shaha, et al. Identification of Angiogenesis/Metastases Genes Predicting Chemoradiotherapy Response in Patients With Laryngopharyngeal Carcinoma J. Clin. Oncol., April 10, 2007; 25(11): 1369 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Shaffer, M. A. Leversha, D. C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu, A. Anand, K. Smith, P. Maslak, G. V. Doyle, et al. Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2023 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Murphy, C. A. Hughes, C. Barrett, H. Magee, B. Loftus, J. J. O'Leary, and O. Sheils Low-Level TOP2A Amplification in Prostate Cancer Is Associated with HER2 Duplication, Androgen Resistance, and Decreased Survival Cancer Res., March 15, 2007; 67(6): 2893 - 2898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Agus, C. J. Sweeney, M. J. Morris, D. S. Mendelson, D. G. McNeel, F. R. Ahmann, J. Wang, M. K. Derynck, K. Ng, B. Lyons, et al. Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy J. Clin. Oncol., February 20, 2007; 25(6): 675 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Solit and N. Rosen Targeting HER2 in Prostate Cancer: Where to Next? J. Clin. Oncol., January 20, 2007; 25(3): 241 - 243. [Full Text] [PDF]
|
|
|
|
|
|
J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al. Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Goldstein, O. Gofrit, A. Nyska, and S. Benita Anti-HER2 Cationic Immunoemulsion as a Potential Targeted Drug Delivery System for the Treatment of Prostate Cancer Cancer Res., January 1, 2007; 67(1): 269 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Inoue, T. Yoshida, Y. Shimizu, T. Kobayashi, T. Yamasaki, Y. Toda, T. Segawa, T. Kamoto, E. Nakamura, and O. Ogawa Requirement of Androgen-Dependent Activation of Protein Kinase C{zeta} for Androgen-Dependent Cell Proliferation in LNCaP Cells and Its Roles in Transition to Androgen-Independent Cells Mol. Endocrinol., December 1, 2006; 20(12): 3053 - 3069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Priolo, D. Tang, M. Brahamandan, B. Benassi, E. Sicinska, S. Ogino, A. Farsetti, A. Porrello, S. Finn, J. Zimmermann, et al. The Isopeptidase USP2a Protects Human Prostate Cancer from Apoptosis. Cancer Res., September 1, 2006; 66(17): 8625 - 8632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Berger, D. I. Lin, M. Nieto, E. Sicinska, L. A. Garraway, H. Adams, S. Signoretti, W. C. Hahn, and M. Loda Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells Cancer Res., June 1, 2006; 66(11): 5723 - 5728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Li, M. Szabolcs, J. D. Terwilliger, and A. Efstratiadis Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene Carcinogenesis, May 1, 2006; 27(5): 1054 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. H. Koumakpayi, J.-S. Diallo, C. Le Page, L. Lessard, M. Gleave, L. R. Begin, A.-M. Mes-Masson, and F. Saad Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clin. Cancer Res., May 1, 2006; 12(9): 2730 - 2737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Edwards, P. Traynor, A. F. Munro, C. F. Pirret, B. Dunne, and J. M.S. Bartlett The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer Clin. Cancer Res., January 1, 2006; 12(1): 123 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Veeramani, T.-C. Yuan, S.-J. Chen, F.-F. Lin, J. E Petersen, S. Shaheduzzaman, S. Srivastava, R. G MacDonald, and M.-F. Lin Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 805 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liu, H. Li, M. Derouet, J. Filmus, E. C. LaCasse, R. G. Korneluk, R. S. Kerbel, and K. V. Rosen ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells: EPIDERMAL GROWTH FACTOR RECEPTOR-DEPENDENT AND -INDEPENDENT MECHANISMS OF ras-INDUCED TRANSFORMATION J. Biol. Chem., November 11, 2005; 280(45): 37383 - 37392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher and C. L. Sawyers Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Hueman, Z. A. Dehqanzada, T. E. Novak, J. M. Gurney, M. M. Woll, G. B. Ryan, C. E. Storrer, C. Fisher, D. G. McLeod, C. G. Ioannides, et al. Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients Clin. Cancer Res., October 15, 2005; 11(20): 7470 - 7479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chen, S. Meng, H. Wang, P. Bali, W. Bai, B. Li, P. Atadja, K. N. Bhalla, and J. Wu Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824 Mol. Cancer Ther., September 1, 2005; 4(9): 1311 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Atkins, M. Regan, D. McDermott, J. Mier, E. Stanbridge, A. Youmans, P. Febbo, M. Upton, M. Lechpammer, and S. Signoretti Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3714 - 3721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, S. Majumder, W. McCall, C. I. Sartor, J. L. Mohler, C. W. Gregory, H. S. Earp, and Y. E. Whang Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer Cancer Res., April 15, 2005; 65(8): 3404 - 3409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Grizzle, D. G. Bostwick, H. Burke, O. W. Tawfik, D. McGregor, J. Cohn, and R. Lieberman Biomarkers in Prostate Cancer Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 196 - 204. [Full Text] [PDF]
|
|
|
|
|
|
T.-L. Cha, L. Qiu, C.-T. Chen, Y. Wen, and M.-C. Hung Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth Cancer Res., March 15, 2005; 65(6): 2287 - 2295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Gregory, Y. E. Whang, W. McCall, X. Fei, Y. Liu, L. A. Ponguta, F. S. French, E. M. Wilson, and H. S. Earp III Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth Clin. Cancer Res., March 1, 2005; 11(5): 1704 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Papandreou and C. J. Logothetis Bortezomib as a Potential Treatment for Prostate Cancer Cancer Res., August 1, 2004; 64(15): 5036 - 5043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Carles, J. Lloreta, M. Salido, A. Font, M. Suarez, V. Baena, M. Nogue, M. Domenech, and X. Fabregat Her-2/neu Expression in Prostate Cancer: A Dynamic Process? Clin. Cancer Res., July 15, 2004; 10(14): 4742 - 4745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Daaka G Proteins in Cancer: The Prostate Cancer Paradigm Sci. Signal., January 20, 2004; 2004(216): re2 - re2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Letsch, A. V. Schally, K. Szepeshazi, G. Halmos, and A. Nagy Preclinical Evaluation of Targeted Cytotoxic Luteinizing Hormone-Releasing Hormone Analogue AN-152 in Androgen-Sensitive and Insensitive Prostate Cancers Clin. Cancer Res., October 1, 2003; 9(12): 4505 - 4513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Bookout, A. E. Finney, R. Guo, K. Peppel, W. J. Koch, and Y. Daaka Targeting G{beta}{gamma} Signaling to Inhibit Prostate Tumor Formation and Growth J. Biol. Chem., September 26, 2003; 278(39): 37569 - 37573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rossi, E. Graner, P. Febbo, L. Weinstein, N. Bhattacharya, T. Onody, G. Bubley, S. Balk, and M. Loda Fatty Acid Synthase Expression Defines Distinct Molecular Signatures in Prostate Cancer Mol. Cancer Res., August 1, 2003; 1(10): 707 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Majumder, J. J. Yeh, D. J. George, P. G. Febbo, J. Kum, Q. Xue, R. Bikoff, H. Ma, P. W. Kantoff, T. R. Golub, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model PNAS, June 24, 2003; 100(13): 7841 - 7846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Pinthus, T. Waks, K. Kaufman-Francis, D. G. Schindler, A. Harmelin, H. Kanety, J. Ramon, and Z. Eshhar Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptor-redirected Human Lymphocytes Cancer Res., May 15, 2003; 63(10): 2470 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Bakin, D. Gioeli, R. A. Sikes, E. A. Bissonette, and M. J. Weber Constitutive Activation of the Ras/Mitogen-activated Protein Kinase Signaling Pathway Promotes Androgen Hypersensitivity in LNCaP Prostate Cancer Cells Cancer Res., April 15, 2003; 63(8): 1981 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Calvo, A. M. Levine, M. Marcos, Q. F. Collins, M. V. Iacocca, L. S. Caskey, C. W. Gregory, Y. Lin, Y. E. Whang, H. S. Earp, et al. Human Epidermal Receptor-2 Expression in Prostate Cancer Clin. Cancer Res., March 1, 2003; 9(3): 1087 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Di Lorenzo, G. Tortora, F. P. D'Armiento, G. De Rosa, S. Staibano, R. Autorino, M. D'Armiento, M. De Laurentiis, S. De Placido, G. Catalano, et al. Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3438 - 3444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mendoza, G. L. Phillips, J. Silva, R. Schwall, and D. Wickramasinghe Inhibition of Ligand-mediated HER2 Activation in Androgen-independent Prostate Cancer Cancer Res., October 1, 2002; 62(19): 5485 - 5488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. K. Mellinghoff, C. Tran, and C. L. Sawyers Growth Inhibitory Effects of the Dual ErbB1/ErbB2 Tyrosine Kinase Inhibitor PKI-166 on Human Prostate Cancer Xenografts Cancer Res., September 15, 2002; 62(18): 5254 - 5259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Solit, F. F. Zheng, M. Drobnjak, P. N. Munster, B. Higgins, D. Verbel, G. Heller, W. Tong, C. Cordon-Cardo, D. B. Agus, et al. 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts Clin. Cancer Res., May 1, 2002; 8(5): 986 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fizazi, L. A. Martinez, C. R. Sikes, D. A. Johnston, L. C. Stephens, T. J. McDonnell, C. J. Logothetis, J. Trapman, L. L. Pisters, N. G. Ordonez, et al. The Association of p21(WAF-1/CIP1) with Progression to Androgen-independent Prostate Cancer Clin. Cancer Res., March 1, 2002; 8(3): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Savinainen, O. R. Saramaki, M. J. Linja, O. Bratt, T. L. J. Tammela, J. J. Isola, and T. Visakorpi Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer Am. J. Pathol., January 1, 2002; 160(1): 339 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Osman, H. I. Scher, M. Drobnjak, D. Verbel, M. Morris, D. Agus, J. S. Ross, and C. Cordon-Cardo HER-2/neu (p185neu) Protein Expression in the Natural or Treated History of Prostate Cancer Clin. Cancer Res., September 1, 2001; 7(9): 2643 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. de Pinieux, M.-E. Legrier, F. Poirson-Bichat, Y. Courty, R. Bras-Goncalves, A.-M. Dutrillaux, F. Nemati, S. Oudard, R. Lidereau, P. Broqua, et al. Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic Approach Am. J. Pathol., August 1, 2001; 159(2): 753 - 764. [Abstract] [Full Text]
|
|
|
|
|
|
S. Signoretti and M. Loda Estrogen Receptor {beta} in Prostate Cancer : Brake Pedal or Accelerator? Am. J. Pathol., July 1, 2001; 159(1): 13 - 16. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Tahir, G. Yang, S. Ebara, T. L. Timme, T. Satoh, L. Li, A. Goltsov, M. Ittmann, J. D. Morrisett, and T. C. Thompson Secreted Caveolin-1 Stimulates Cell Survival/Clonal Growth and Contributes to Metastasis in Androgen-insensitive Prostate Cancer Cancer Res., May 1, 2001; 61(10): 3882 - 3885. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. I. Scher HER2 in Prostate Cancer--a Viable Target or Innocent Bystander? J Natl Cancer Inst, December 6, 2000; 92(23): 1866 - 1868. [Full Text] [PDF]
|
|